Intercept Pharmaceuticals Inc (ICPT)

113.72
1.45 1.29
NASDAQ : Health Care
Prev Close 112.27
Open 113.00
Day Low/High 112.20 / 114.40
52 Wk Low/High 89.76 / 285.00
Volume 356.24K
Avg Volume 376.60K
Exchange NASDAQ
Shares Outstanding 25.01M
Market Cap 2.90B
EPS -16.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Movers: Paratek Spikes 34%

Biotech Movers: Paratek Spikes 34%

Paratek Pharmaceuticals, Immunomedics and Intercept Pharmaceuticals were among the biotech stock movers in premarket trading Tuesday.

Full Speed Ahead; Big Moves: Best of Kass

Full Speed Ahead; Big Moves: Best of Kass

In highlights from this week's trading diary and posts, Kass offers some advice about fundamentals and about what earnings season means.

Intercept Pharmaceuticals Plans Changes to Its Fatty Liver Disease Study

Intercept Pharmaceuticals Plans Changes to Its Fatty Liver Disease Study

Intercept says it received approval from the FDA.

Intercept Pharma: We Can't Enroll Our NASH Study so We're Changing the Study. Trust Us, All Good

Intercept Pharma: We Can't Enroll Our NASH Study so We're Changing the Study. Trust Us, All Good

Intercept claims FDA approved the OCA study modifications, but like most pharma companies, no proof was offered, just verbal assurances.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.

Intercept To Provide Update On Phase 3 REGENERATE Trial Of Obeticholic Acid For The Treatment Of NASH Patients With Liver Fibrosis

Intercept To Provide Update On Phase 3 REGENERATE Trial Of Obeticholic Acid For The Treatment Of NASH Patients With Liver Fibrosis

Company to host investor conference call today at 8:30 a.m. ET

Notable Wednesday Option Activity: ICPT, ODFL, DRRX

Notable Wednesday Option Activity: ICPT, ODFL, DRRX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intercept Pharmaceuticals Inc , where a total of 2,193 contracts have traded so far, representing approximately 219,300 underlying shares. That amounts to about 51.3% of ICPT's average daily trading volume over the past month of 427,725 shares.

Intercept Presents New Data At AASLD Examining The Effects Of Ocaliva® (Obeticholic Acid) On Non-Invasive Assessments Of Liver Fibrosis In Patients With PBC

Intercept Presents New Data At AASLD Examining The Effects Of Ocaliva® (Obeticholic Acid) On Non-Invasive Assessments Of Liver Fibrosis In Patients With PBC

Poster presentations explore changes in biochemical markers of disease progression in PBC patients with cirrhosis and renal impairment

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

But we could see more volatility in the market.

Intercept Announces Ocaliva® (Obeticholic Acid) Data In PBC To Be Presented At The 2016 AASLD Annual Meeting

Intercept Announces Ocaliva® (Obeticholic Acid) Data In PBC To Be Presented At The 2016 AASLD Annual Meeting

Intercept will collaborate with academic leaders on a new NASH patient registry

Gilead Sciences Advances Fatty Liver Drug, Causing Some Head-Scratching

Gilead Sciences Advances Fatty Liver Drug, Causing Some Head-Scratching

Gilead is under enormous pressure from investors to acquire companies or develop new drugs from its pipeline.

Here's Why You Should Consider Tesla's Convertible Bonds

Here's Why You Should Consider Tesla's Convertible Bonds

Investors seeking to bet against Tesla's common stock may want to give its convertible bonds a spin.

How To Bet Against Tesla Using Convertible Bonds

How To Bet Against Tesla Using Convertible Bonds

Investors seeking to bet against Tesla's common stock may want to give its convertible bonds a spin.

Allergan's Boldness may not be Limited to Tobira Deal

Allergan's Boldness may not be Limited to Tobira Deal

The Irish drugmaker isn't likely done making deals, even though it just made two, and it could take a look at Alder Biopharmaceuticals next, analysts believe.